> Skip to main content
Hillman Ventures — Dallas Family Office, est. 1995
Read in
Connect LinkedIn Substack X / @ajhusa Instagram TikTok Pinterest GitHub
Hillman Ventures official brand mark, mountain peaks with upward arrow

Dallas, Texas. Founded 1995.

Regulatory Reference
Regenerative Medicine Laws by Jurisdiction. Working registry across the EU, broader Europe, Latin America, the Middle East, and beyond. Open the registry →

A private family office for frontier biotech.

Hillman Ventures invests personal capital into therapeutic platforms targeting inflammation, damaged tissue, and tumor-based cancers. Founder-aligned, long-horizon, regulatory-fluent. Stewarded by Andrew Jonathan Hillman from Dallas, Texas.

I. The Thesis

Three priorities. One horizon.

The fund concentrates personal capital on platforms with deep biological rationale and a credible path through U.S. FDA biologics frameworks. Every investment is reviewed on the same three lenses.

Inflammation

Modulating chronic and acute inflammatory cascades through biologics, exosome science, and small-molecule pathways. Where standard-of-care still leans on broad immunosuppression, we look for precision tools.

Damaged Tissue

Regenerative therapies for musculoskeletal injury, degenerative disc disease, post-surgical recovery, and orthobiologic indications. Platforms that combine biological signal with clean CMC and a defensible regulatory pathway.

Tumor-Based Cancers

Targeted oncology platforms with novel mechanisms of action, including osmotic lysis, immunomodulation, and tumor-microenvironment disruption. The shared filter is a credible IND-enabling roadmap.

II. The Approach

Capital with operator judgment behind it.

Hillman Ventures is not a fund. It is personal capital deployed by an operator with three decades inside FDA-regulated healthcare ventures. Investments are made for fundamental, multi-decade reasons. The portfolio does not chase quarters.

Andrew brings the regulatory sophistication of a senior paralegal and an expert witness on healthcare compliance and FDA enforcement. That seat informs every diligence call.

  • Long horizon.Investments held for clinical and regulatory cycles, not exit windows.
  • Founder aligned.Concentrated check sizes with deep founder relationships. No board theatre.
  • Regulatory fluent.Pathway analysis (351a vs 361, RMAT, 510k, Pre-IND Type B) is foundational, not an afterthought.
  • CMC rigorous.Manufacturing standards, certificate of analysis, and process scalability evaluated up front.
  • Quietly involved.We help with regulatory questions, CMC strategy, and litigation defense. We do not brand portfolio companies.

The Holding Company

A consolidated structure for long horizons.

Hillman Ventures sits at the top of a consolidated holding structure. Each operating subsidiary runs under its own management, regulatory file, and capital plan. Consolidation is reserved for governance, tax, and capital allocation. Daily operations stay close to the science.

The structure is designed to hold positions across decades, not quarters. Operating entities include FDA-regulated biologics, oncology, regenerative medicine, advisory services, and real property.

  • Mesenchymal exosome biologics program. WJ-MSC exosome biologics.
  • the TOL program sponsor. Targeted Osmotic Lysis.
  • Hillman Advisory. FDA and capital counsel.
  • DICOE. Regenerative medicine clinic platform.
  • CORE Tijuana. International strategic partner.
  • Real property. 901 Main and operating real estate.
Hillman Ventures holding company architecture. Modern corporate building with Holding Company signage.

The Hillman Ventures holding structure. Consolidated for governance, decentralized for operations.

III. The Principal

HV

Andrew Jonathan Hillman

Principal & Founder

Andrew has operated FDA-regulated healthcare ventures for three decades, including a 510(k)-cleared orthobiologics company divested in 2021. He is a senior paralegal and investigator at a Dallas private law firm focused on healthcare compliance and FDA regulatory matters, and an expert witness on healthcare compliance, hospital operations, FDA enforcement, and healthcare finance.

He was the named federal class action plaintiff in Hillman v. Ringleader Digital (S.D.N.Y.), a privacy case settled with industry-side reform and cited in the American Inns of Court Cyber Security CLE curriculum, and in Levine et al. v. Google, Inc. (N.D. Cal.).

Andrew HillmanHe founded the Andrew Hillman Scholarship for Entrepreneurs (founded 2024) (2020) and the Andrew Hillman Grant for Biotech (founded 2026) (2026), each a one-thousand-dollar annual award for U.S. undergraduates, funded from personal savings. He established the Andrew Hillman Family Room at the Lamplighter School in Dallas with a three-hundred-thousand-dollar family gift supporting robotics instruction.

Complete factual record at andrewhillmanrecord.com.

Dallas, Texas

IV. Field Notes

The Hillman Letter.

A monthly long-form letter on frontier biotech investing, FDA regulatory strategy, federal class action plaintiff perspective, and the Restart book project. One issue per month, first Monday, in writing, on our own terms.

Subscribe to The Letter
  • IMDb
    • Medium archive

    V. Coverage

    Independent press.

    Third-party coverage of the founder, the programs, and the Hillman Ventures positioning.

    October 2025

    Opportunity Alert: Andrew Hillman Grant for Biotech

    Apple Podcasts — NewsRamp Science, Exploration and Discovery

    February 2026

    Andrew Hillman Announces the Andrew Hillman Grant for Biotech

    GlobeNewswire

    June 2024

    Andrew Hillman of Dallas Launches Scholarship for Entrepreneurs

    Yahoo Finance

    April 2024

    Andrew Hillman of Dallas Announces Scholarship for Entrepreneurs

    PR Newswire

    Full press wall at andrewhillmanrecord.com.

    VI. Contact

    Inquiries.

    For partner introductions, regulatory consultation, expert witness engagement, scholarship and grant questions, and press.

    General

    [email protected]

    Press

    [email protected]

    Programs

    andrewhillmanscholarship.com
    andrewhillmangrant.com

    Speaking and Expert Witness

    Booking through andrewhillman.org

    Researcher Identifier

    ORCID 0009-0001-5396-321X

    Andrew Hillman portraitAndrew Hillman portraitAndrew Hillman portraitAndrew Hillman portrait
    The Hillman Cluster

    Sister sites with the rest of the record. Every property is independently verifiable.

    Andrew Hillman cluster source - favicons?sz=32&domain=andrew hillmanAndrew Hillman · PrincipalAndrew Hillman cluster source - favicons?sz=32&domain=andrewhillmanrecordThe Public Record · Primary SourcesAndrew Hillman cluster source - favicons?sz=32&domain=andrewhillmanadvisorAdvisor · FDA & BiotechAndrew Hillman cluster source - favicons?sz=32&domain=fixcancerFixCancer.org · TOLAndrew Hillman cluster source - favicons?sz=32&domain=andrewhillmanService Before Scale · NonprofitAndrew Hillman cluster source - favicons?sz=32&domain=andrewjhillmanExpert Witness · DaubertSubstack logoThe Hillman Letter · Substack
    Connect on LinkedIn 21,922 followers

    Verified primary sources

    Every claim on this network traces to one of ten independent primary surfaces. Three federal. Two registries. Two state and accreditation. Three top-tier press archives.

    Investor relations

    Read the letter. Then talk to us.

    Quarterly portfolio letters and family-office structure. Investor introductions through warm intros only.

    Q2 2026 portfolio letter Connect on LinkedIn The Hillman Letter